![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN
HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY)
|
|
|
IAS 2021 July 18-22
Bronagh Shepherd,1 Moti Ramgopal,2 Peter Ackerman,3 Shiven Chabria,3 Fangfang Du,4 Marcia Wang,4 Amy Pierce,5 Andrew Clark6
1GlaxoSmithKline, Uxbridge, UK; 2Midway Specialty Care Center, Fort Pierce, FL, USA; 3ViiV Healthcare, Branford, CT, USA; 4GlaxoSmithKline, Collegeville, PA, USA;
5ViiV Healthcare, Research Triangle Park, NC, USA; 6ViiV Healthcare, Brentford, UK
![0722211](../images/072221/072221-13/0722211.gif)
![0722212](../images/072221/072221-13/0722212.gif)
![0722213](../images/072221/072221-13/0722213.gif)
![0722214](../images/072221/072221-13/0722214.gif)
![0722215](../images/072221/072221-13/0722215.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|